DxWound harnesses the precision and sensitivity of genomic technology to provide a consolidated solution geared specifically to wound care providers.
Discover the benefits of DNA-based diagnostic testing to help clinicians rapidly determine course of therapy for patients with suspected wound infections.
Using tiny amounts of microbial DNA as starting material, DxWound provides accurate, sensitive detection of an array of microbes, including aerobic/anaerobic bacteria and fungi, plus antibiotic resistance genes – all delivered in a single actionable report typically within one business day.*
DxWound equips clinicians with comprehensive information about the wound microbiome that may help them effectively and rapidly navigate important treatment decisions for their patients, including:
Discover the next era of diagnostic testing that may help alleviate some of the trial-and-error of managing wound infections. Rapid, comprehensive and actionable testing means clinicians can spend more time focused on healing their patient’s wound– and less time trying to resolve infections.
The wound microbiome is highly diverse and can be populated with microbial species that are not routinely tested for using traditional laboratory methods.1
of chronic wounds of various etiologies can be populated by anaerobic bacteria, including strict anaerobes,1 and fungal species that are known opportunistic pathogens2
The diversity of the wound microbiome may make it challenging to empirically select antibiotics that effectively target the causative agent.1
A recent study demonstrated that initial treatment failure was experienced in as many as3
16.6% of acute SSTIs,
26.7% of surgical site infections, and
34.1% of chronic or ulcerative infections
Effectively targeting antimicrobial therapy to the causative agent, especially within 48 hours, may reduce risk for treatment failure4, and poor patient outcomes such as extended hospital LOS, and increased mortality5.
Rapid. Next business day results can help accelerate clinical decision making for patients.
Comprehensive. Accuracy and precision of DNA-based detections allows clinicians to evaluate more than the usual suspects.
Actionable. Transform diagnostic test results into decisions with user-friendly, actionable reporting.
The CogenDx logo is a service mark or registered service mark of Millennium Health, LLC or its subsidiaries in the United States and other Countries. All other trademarks used herein are the property of their respective owners. These clinical laboratory developed tests (LDTs) were developed and their performance characteristics determined by Millennium Health, LLC and have not been cleared or approved by the US Food and Drug Administration (FDA). These LDTs are clinical tests and their results should be used with other clinical observations and diagnostic findings for patient case management. Millennium Health, LLC maintains certification in accordance with Clinical Laboratory Improvement Amendments of 1988 and is accredited by the College of American Pathologists.